- Home
- EVGO vs GHRS Comparison
EVGO vs GHRS Comparison
Compare EVGO & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGO
- GHRS
- Stock Information
- Founded
- EVGO 2010
- GHRS 2018
- Country
- EVGO United States
- GHRS Ireland
- Employees
- EVGO N/A
- GHRS N/A
- Industry
- EVGO Other Specialty Stores
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- EVGO Consumer Discretionary
- GHRS Health Care
- Exchange
- EVGO Nasdaq
- GHRS Nasdaq
- Market Cap
- EVGO 674.8M
- GHRS 774.1M
- IPO Year
- EVGO N/A
- GHRS 2021
- Fundamental
- Price
- EVGO $4.11
- GHRS $14.32
- Analyst Decision
- EVGO Buy
- GHRS Strong Buy
- Analyst Count
- EVGO 8
- GHRS 9
- Target Price
- EVGO $5.70
- GHRS $29.33
- AVG Volume (30 Days)
- EVGO 3.9M
- GHRS 280.2K
- Earning Date
- EVGO 11-10-2025
- GHRS 11-07-2025
- Dividend Yield
- EVGO N/A
- GHRS N/A
- EPS Growth
- EVGO N/A
- GHRS N/A
- EPS
- EVGO N/A
- GHRS N/A
- Revenue
- EVGO $308,365,000.00
- GHRS N/A
- Revenue This Year
- EVGO $45.13
- GHRS N/A
- Revenue Next Year
- EVGO $26.83
- GHRS N/A
- P/E Ratio
- EVGO N/A
- GHRS N/A
- Revenue Growth
- EVGO 49.06
- GHRS N/A
- 52 Week Low
- EVGO $2.20
- GHRS $6.72
- 52 Week High
- EVGO $8.42
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- EVGO 44.48
- GHRS 55.19
- Support Level
- EVGO $3.81
- GHRS $12.50
- Resistance Level
- EVGO $4.29
- GHRS $14.44
- Average True Range (ATR)
- EVGO 0.22
- GHRS 1.00
- MACD
- EVGO -0.06
- GHRS 0.03
- Stochastic Oscillator
- EVGO 30.96
- GHRS 76.87
About EVGO EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.